FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133221875> ?p ?o ?g. }

• W2133221875 endingPage "2846" @default.
• W2133221875 startingPage "2839" @default.
• W2133221875 abstract "Purpose Apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (Apo2L/TRAIL)—a member of the tumor necrosis factor cytokine family—induces apoptosis by activating the extrinsic pathway through the proapoptotic death receptors DR4 and DR5. Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy. To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer. Patients and Methods This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2). Doses were given daily for 5 days, with cycles repeating every 3 weeks. Assessments included adverse events (AEs), laboratory tests, pharmacokinetics, and imaging to evaluate antitumor activity. Results Seventy-one patients received a mean of 18.3 doses; seven patients completed all eight treatment cycles. The AE profile of rhApo2L/TRAIL was similar in cohorts 1 and 2. The most common AEs were fatigue (38%), nausea (28%), vomiting (23%), fever (23%), anemia (18%), and constipation (18%). Liver enzyme elevations were concurrent with progressive metastatic liver disease. Two patients with sarcoma (synovial and undifferentiated) experienced serious AEs associated with rapid tumor necrosis. Two patients with chondrosarcoma experienced durable partial responses to rhApo2L/TRAIL. Conclusion At the tested schedule and dose range, rhApo2L/TRAIL was safe and well tolerated. Dose escalation achieved peak rhApo2L/TRAIL serum concentrations equivalent to those associated with preclinical antitumor efficacy." @default.
• W2133221875 created "2016-06-24" @default.
• W2133221875 creator A5005775401 @default.
• W2133221875 creator A5008593691 @default.
• W2133221875 creator A5016309859 @default.
• W2133221875 creator A5016706552 @default.
• W2133221875 creator A5028133447 @default.
• W2133221875 creator A5028533192 @default.
• W2133221875 creator A5039774247 @default.
• W2133221875 creator A5053481267 @default.
• W2133221875 creator A5060799552 @default.
• W2133221875 creator A5069690249 @default.
• W2133221875 creator A5075298687 @default.
• W2133221875 creator A5075801763 @default.
• W2133221875 creator A5079101064 @default.
• W2133221875 date "2010-06-10" @default.
• W2133221875 modified "2023-10-16" @default.
• W2133221875 title "Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer" @default.
• W2133221875 cites W1607911699 @default.
• W2133221875 cites W1964304371 @default.
• W2133221875 cites W1977885634 @default.
• W2133221875 cites W1978480779 @default.
• W2133221875 cites W1981634943 @default.
• W2133221875 cites W1987506447 @default.
• W2133221875 cites W2011401291 @default.
• W2133221875 cites W2015879631 @default.
• W2133221875 cites W2016544505 @default.
• W2133221875 cites W2020439083 @default.
• W2133221875 cites W2023287155 @default.
• W2133221875 cites W2025128734 @default.
• W2133221875 cites W2034269086 @default.
• W2133221875 cites W2038118195 @default.
• W2133221875 cites W2039805273 @default.
• W2133221875 cites W2045576568 @default.
• W2133221875 cites W2046424185 @default.
• W2133221875 cites W2055905844 @default.
• W2133221875 cites W2079463756 @default.
• W2133221875 cites W2080613199 @default.
• W2133221875 cites W2088580558 @default.
• W2133221875 cites W2097786201 @default.
• W2133221875 cites W2105441981 @default.
• W2133221875 cites W2106284224 @default.
• W2133221875 cites W2119326933 @default.
• W2133221875 cites W2125988618 @default.
• W2133221875 cites W2139248078 @default.
• W2133221875 cites W2142561620 @default.
• W2133221875 cites W2150758813 @default.
• W2133221875 cites W2323955045 @default.
• W2133221875 doi "https://doi.org/10.1200/jco.2009.25.1991" @default.
• W2133221875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20458040" @default.
• W2133221875 hasPublicationYear "2010" @default.
• W2133221875 type Work @default.
• W2133221875 sameAs 2133221875 @default.
• W2133221875 citedByCount "378" @default.
• W2133221875 countsByYear W21332218752012 @default.
• W2133221875 countsByYear W21332218752013 @default.
• W2133221875 countsByYear W21332218752014 @default.
• W2133221875 countsByYear W21332218752015 @default.
• W2133221875 countsByYear W21332218752016 @default.
• W2133221875 countsByYear W21332218752017 @default.
• W2133221875 countsByYear W21332218752018 @default.
• W2133221875 countsByYear W21332218752019 @default.
• W2133221875 countsByYear W21332218752020 @default.
• W2133221875 countsByYear W21332218752021 @default.
• W2133221875 countsByYear W21332218752022 @default.
• W2133221875 countsByYear W21332218752023 @default.
• W2133221875 crossrefType "journal-article" @default.
• W2133221875 hasAuthorship W2133221875A5005775401 @default.
• W2133221875 hasAuthorship W2133221875A5008593691 @default.
• W2133221875 hasAuthorship W2133221875A5016309859 @default.
• W2133221875 hasAuthorship W2133221875A5016706552 @default.
• W2133221875 hasAuthorship W2133221875A5028133447 @default.
• W2133221875 hasAuthorship W2133221875A5028533192 @default.
• W2133221875 hasAuthorship W2133221875A5039774247 @default.
• W2133221875 hasAuthorship W2133221875A5053481267 @default.
• W2133221875 hasAuthorship W2133221875A5060799552 @default.
• W2133221875 hasAuthorship W2133221875A5069690249 @default.
• W2133221875 hasAuthorship W2133221875A5075298687 @default.
• W2133221875 hasAuthorship W2133221875A5075801763 @default.
• W2133221875 hasAuthorship W2133221875A5079101064 @default.
• W2133221875 hasConcept C121608353 @default.
• W2133221875 hasConcept C126322002 @default.
• W2133221875 hasConcept C143998085 @default.
• W2133221875 hasConcept C17991360 @default.
• W2133221875 hasConcept C197934379 @default.
• W2133221875 hasConcept C2778375690 @default.
• W2133221875 hasConcept C2780580376 @default.
• W2133221875 hasConcept C2780852908 @default.
• W2133221875 hasConcept C71924100 @default.
• W2133221875 hasConcept C90924648 @default.
• W2133221875 hasConceptScore W2133221875C121608353 @default.
• W2133221875 hasConceptScore W2133221875C126322002 @default.
• W2133221875 hasConceptScore W2133221875C143998085 @default.
• W2133221875 hasConceptScore W2133221875C17991360 @default.
• W2133221875 hasConceptScore W2133221875C197934379 @default.
• W2133221875 hasConceptScore W2133221875C2778375690 @default.
• W2133221875 hasConceptScore W2133221875C2780580376 @default.
• W2133221875 hasConceptScore W2133221875C2780852908 @default.

• next